Max Healthcare inks pact for genomics research with Anuva

Max Healthcare inks pact for genomics research with Anuva

The pact involves Max Healthcare providing its expertise in clinical research along with a base for data and sample collection.

FPJ Web DeskUpdated: Tuesday, December 27, 2022, 10:13 PM IST
article-image

Max Healthcare and genomics biotech firm Anuva have joined forces to for genomic-based research focusing on communicable and non-communicable diseases in India, through an MoU. To be conducted over the next five years, the research will seek insights on application of precision medicine for breast cancer, lung cancer, diabetes, cardiac disease, kidney disease, and drug resistant tuberculosis, among others.

The pact involves Max Healthcare providing its expertise in clinical research along with a base for data and sample collection

Anuva provides translational research for a diverse genomic bio and data bank that will cater to Asian populations. The agreement also involves working on the possibility of conducting joint training, fellowships, exchange visits, knowledge and technology transfer.

RECENT STORIES

PLI For Specialty Steel Sees Investments Worth ₹23,022 Crore Till October: Centre

PLI For Specialty Steel Sees Investments Worth ₹23,022 Crore Till October: Centre

JSW Defence Kick-Starts USD 90-mn Project For Military Drone Manufacturing With US Partner Shield AI

JSW Defence Kick-Starts USD 90-mn Project For Military Drone Manufacturing With US Partner Shield AI

Adani Completes ₹231 Crore Acquisition Of Trade Castle Tech Park To Boost AdaniConneX...

Adani Completes ₹231 Crore Acquisition Of Trade Castle Tech Park To Boost AdaniConneX...

Govt To Divest 6 Per Cent Stake In Bank Of Maharashtra After OFS Sees 400 Pc Subscription; Nearly...

Govt To Divest 6 Per Cent Stake In Bank Of Maharashtra After OFS Sees 400 Pc Subscription; Nearly...

US Sanctions Cut India’s Russian Oil Imports By One-Third; December Arrivals May Dip Further As...

US Sanctions Cut India’s Russian Oil Imports By One-Third; December Arrivals May Dip Further As...